CD274 and breast cancer: Additionally, given the active role of immune checkpoint inhibition in the treatment of BC, our study’s findings could pave the way for novel combination therapy approaches, taken together with recent evidence that RAS pharmacologic inhibition with the use of an ACEI or ARB can potentiate the tumoricidal effects of PD-1/PD-L1 inhibitors in patients with metastatic urothelial BC [28].